# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESR 1150 CL in Healthy Subjects

> **NCT02209688** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 39 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ESR 1150 CL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02209688
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-02
- **Primary completion:** 2000-03
- **Final completion:** —
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2014-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02209688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02209688, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESR 1150 CL in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02209688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*